Trust Signals
- Written by FormBlends Medical Team, reviewed against primary literature on PubMed and FDA labeling documents.
- No peptide brand relationships. Where evidence is weak, we say so explicitly.
- Every claim graded by evidence type in the ledger table below.
- Last reviewed and updated: May 29, 2026.
Key Takeaways
- Tesamorelin is the only FDA-approved peptide in this group, approved in 2010 for HIV-associated lipodystrophy, with phase 3 RCT data showing roughly 15 to 18 percent visceral fat reduction over 26 weeks.
- CJC-1295 with DAC has a plasma half-life of approximately 6 to 8 days due to albumin binding, versus roughly 10 to 20 minutes for sermorelin, a pharmacokinetic difference that changes dosing schedules entirely.
- Ipamorelin acts on ghrelin receptors (GHSR-1a), not GHRH receptors, making it a mechanistically distinct partner for GHRH-class peptides rather than a substitute for them.
- No published human RCT demonstrates that the CJC-1295 plus ipamorelin combination outperforms either agent alone for body composition in healthy adults.
- All four peptides are prohibited by WADA under the S2 category and carry class-level risks including glucose intolerance documented in tesamorelin's approved label.
What Is the Practical Difference Between These Four Peptides in Plain Terms?
Sermorelin and tesamorelin are GHRH analogues that tell the pituitary to release more GH per pulse. CJC-1295 does the same thing but resists enzymatic breakdown far longer. Ipamorelin mimics ghrelin at a different receptor to increase how often GH pulses occur. Tesamorelin is the only one with FDA approval and robust human trial data. For everyone else, the evidence is thinner than most product pages admit.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
How Do the Mechanisms Actually Differ, With Specific Receptor and Half-Life Data?
Sermorelin is a synthetic version of the first 29 amino acids of endogenous human GHRH(1-44). It binds the GHRH receptor (GHRHR) on pituitary somatotrophs. Its main vulnerability is rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at the Ala2 position, producing a plasma half-life reported in the range of 10 to 20 minutes following subcutaneous injection. It stimulates GH release in proportion to existing pituitary reserve, which declines with age.
CJC-1295 without DAC (also sold as modified GRF 1-29) contains four amino acid substitutions compared to natural GHRH: Tyr1 to His, Ala2 to D-Ala (blocking DPP-IV cleavage), Gln8 to Ala, and Leu27 to Arg. These changes extend half-life to approximately 30 minutes, long enough to produce a meaningful GH pulse when dosed immediately before sleep.
CJC-1295 with DAC adds a lysine-linked maleimidopropionic acid (MPA) moiety, the Drug Affinity Complex, that covalently binds circulating albumin through a Michael addition reaction. Albumin's long half-life (roughly 19 days) acts as a depot. Pharmacokinetic data from Walker et al. (2006) in healthy adults showed mean elimination half-life of approximately 6 to 8 days and sustained, non-pulsatile IGF-1 elevations over the dosing interval. This blunts physiological GH pulsatility, which is a legitimate concern (see Section 4).
Ipamorelin is a pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a), the same receptor that endogenous ghrelin activates. Its selectivity means it releases GH with minimal concurrent cortisol, prolactin, or ACTH release at standard doses, a distinction confirmed in animal studies by Raun et al. (1998). Plasma half-life is short, reported at roughly 2 hours in animal pharmacokinetic work. Human PK data in peer-reviewed literature are sparse because ipamorelin did not complete clinical development.
Tesamorelin is the full 44-amino-acid GHRH sequence conjugated to a trans-3-hexenoic acid group at the N-terminus. That modification stabilizes the molecule against DPP-IV and extends half-life to roughly 26 minutes after subcutaneous injection. Phase 3 trials used 2 mg daily subcutaneous dosing. It retains pulsatile GH release because each dose acts within a narrow time window.
Evidence Ledger: What Does the Research Actually Support?
| Claim | Peptide(s) | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| Reduces visceral adipose tissue in HIV lipodystrophy | Tesamorelin | Multiple phase 3 human RCTs (Falutz et al., NEJM 2010; Grunfeld et al.) | Roughly 15 to 18% VAT reduction vs placebo at 26 weeks | High |
| Raises IGF-1 in healthy older adults | Sermorelin, CJC-1295 with DAC | Small human trials (Walker et al. 2006 for CJC-1295; Prakash and Goa 1999 review for sermorelin) | Positive, magnitude varies with pituitary reserve | Moderate |
| Selective GH release without cortisol or prolactin spike | Ipamorelin | Animal studies (Raun et al. 1998) | Positive for selectivity vs GHRP-2, GHRP-6 | Low (human data absent) |
| CJC-1295 plus ipamorelin combination superior to monotherapy for body composition in healthy adults | CJC-1295 plus ipamorelin | No published human RCT found | Unknown | Very Low |
| Improves sleep quality or recovery | All four (claimed broadly) | Mechanism only (GH is naturally sleep-entrained) | Plausible, unproven clinically for secretagogues | Very Low |
| Glucose intolerance as a real adverse effect | Tesamorelin (documented in label); class risk for all | RCT adverse event data (tesamorelin); mechanism for others | Negative (risk increases) | High for tesamorelin; Moderate for class |
| Does not cause pituitary desensitization (preserves feedback) | All four vs exogenous GH | Mechanism and limited human data | Favorable vs exogenous GH, but long-term data lacking | Moderate |
Honest Head-to-Head Comparison Table
| Feature | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) | Ipamorelin | Tesamorelin |
|---|---|---|---|---|---|
| Receptor target | GHRHR | GHRHR | GHRHR | GHSR-1a | GHRHR |
| Plasma half-life | 10 to 20 min | ~30 min | ~6 to 8 days | ~2 hours (animal) | ~26 min |
| Dosing frequency | Daily or nightly | Daily, pre-sleep | 1 to 2x per week | Daily, often 2x to 3x | Daily (approved 2 mg) |
| Preserves GH pulsatility | Yes | Yes | No (blunts pulsatility) | Yes | Yes |
| FDA approval | No (withdrawn as Geref) | No | No | No | Yes (HIV lipodystrophy) |
| Strongest human evidence | Pediatric GHD studies | Walker et al. 2006 (n=65) | Walker et al. 2006 | Raun et al. 1998 (animal) | Phase 3 RCTs (hundreds of patients) |
| Appetite stimulation | Minimal | Minimal | Minimal | Minimal (unlike GHRP-6) | Minimal |
| Cortisol/prolactin release | Low | Low | Low | Very low (selective) | Low |
| Where peptide loses vs alternatives | Less potent than exogenous GH; age-limited | No RCT in body composition | Pulsatility concern; no RCT | Almost no human PK data | Approved only for HIV lipodystrophy; off-label use unproven |
What Most Comparison Pages Get Wrong About These Peptides
Bioavailability from non-injectable routes is essentially zero for all four peptides. These are peptides of 5 to 44 amino acids. Oral administration results in near-complete proteolytic degradation before systemic absorption. Sublingual preparations may show trace absorption at best. Any product claiming meaningful oral or transdermal delivery of intact GHRH-class peptides at pharmacological doses is not supported by published bioavailability data.
Why the Rules of Thumb Exist: The Chemistry Behind Dosing and Storage
Why store lyophilized peptides cold and reconstituted solutions in the refrigerator? Peptide bonds are susceptible to hydrolysis, the rate of which increases with temperature following Arrhenius kinetics. In lyophilized (freeze-dried) form, the absence of water dramatically slows hydrolysis, which is why powder is far more stable than solution. Once water is added during reconstitution, degradation begins. Refrigeration at 2 to 8 degrees Celsius slows but does not stop this process. Freezing reconstituted solution introduces freeze-thaw stress that can cause aggregation, particularly in longer peptides like tesamorelin (44 amino acids) where intermolecular beta-sheet formation is a risk. The 28 to 30 day post-reconstitution use window that compounding pharmacies recommend reflects this kinetic reality, not arbitrary caution.
Why avoid mixing with vitamin C (ascorbic acid) in the same syringe? Ascorbic acid is a reducing agent with a pKa around 4.2. When mixed with peptides that contain cysteine, methionine, or tryptophan residues, it can participate in oxidation-reduction reactions that modify side chains and alter the peptide's three-dimensional binding geometry. None of the four peptides discussed here contain cysteine, but the general rule is correct for the broader peptide class and reflects real redox chemistry rather than myth.
Why does the timing of injection matter? Endogenous GHRH peaks in the early hours of sleep, driving the dominant nocturnal GH pulse. Injecting short-acting GHRH analogues (sermorelin, CJC-1295 without DAC, tesamorelin) before sleep aims to amplify a pulse that is already primed to occur, rather than inducing a pulse in isolation. Insulin-induced hypoglycemia is a potent GH stimulus partly because it happens to coincide with the same GHRH-somatostatin axis timing. Injecting during a somatostatin-high phase (mid-afternoon, post-meal) blunts the GH response even with adequate receptor agonism.
How to Read a Peptide COA and Reconstitution Math
Certificate of Analysis minimums for injectable peptides:
- HPLC purity: greater than 98 percent for research-grade, greater than 99 percent for pharmaceutical-grade
- Mass spectrometry: molecular weight confirmation within 1 dalton of theoretical (tesamorelin theoretical MW approximately 5135 Da; ipamorelin approximately 712 Da; sermorelin approximately 3357 Da; CJC-1295 without DAC approximately 3367 Da)
- Endotoxin: below 5 EU per kg per dose (USP 85 Bacterial Endotoxins Test)
- Sterility: USP 71 or equivalent
- Moisture content: typically less than 5 percent for lyophilized product
Reconstitution math example (CJC-1295 without DAC, 2 mg vial):
- Add 2 mL bacteriostatic water to a 2 mg vial. This gives a concentration of 1 mg per mL, or 1000 micrograms per mL.
- A typical research dose of 100 micrograms requires drawing 0.10 mL on a U-100 insulin syringe (10 units on that syringe).
- A dose of 200 micrograms requires 0.20 mL (20 units). Write these out before reconstituting to avoid dosing errors.
Safety Profile and Risks: Class Effects Versus Compound-Specific Findings
Class-level effects (all four peptides):
- Water retention and peripheral edema from downstream IGF-1 activity
- Joint aches (arthralgias), typically dose-related
- Carpal tunnel symptoms with higher doses or in predisposed individuals
- Elevated fasting glucose via GH-induced insulin resistance (GH is a counter-regulatory hormone)
Compound-specific: Tesamorelin's prescribing information (FDA label) specifically documents glucose intolerance in trial participants. No equivalent adverse event database exists for the other three because they lack completed phase 2 to 3 human trials. Ipamorelin's lack of cortisol and prolactin stimulation at standard doses is a genuine selectivity advantage over older GHRPs, but this is established in rat and porcine models, not large human studies.
Long-term concern: IGF-1 and cancer risk. Elevated IGF-1 is associated epidemiologically with several cancers (colorectal, prostate, breast). Whether pharmacological IGF-1 elevation from secretagogue use meaningfully increases cancer risk over treatment durations of months is not established by any published cohort data for these peptides. The risk is mechanistically plausible and should not be dismissed, particularly in individuals with personal or family cancer history.
How These Peptides Compare to Exogenous GH and IGF-1
| Feature | GH Secretagogues (all 4) | Exogenous Recombinant GH | Exogenous IGF-1 (Mecasermin) |
|---|---|---|---|
| Mechanism | Stimulates endogenous pituitary GH release | Replaces GH directly | Replaces IGF-1 directly, bypasses GH axis |
| Preserves pulsatility and feedback | Yes (except CJC-1295 DAC) | No | Not applicable |
| Suppresses endogenous GH with chronic use | Low risk | Yes, via negative feedback | Yes, GH rises via feedback |
| Human RCT evidence for body composition | Only tesamorelin (HIV-specific) | Multiple RCTs in GH-deficient adults | Limited; FDA approved for primary IGF-1 deficiency |
| Where peptides lose | Require functioning pituitary; age-limited ceiling; no RCT in healthy adults for fat loss | Predictable dose-response, better studied | Predictable IGF-1 elevation regardless of pituitary status |
| Legal status (US) | Compounded; tesamorelin FDA approved | FDA approved for GHD; Schedule III analog concerns off-label | FDA approved for specific deficiency |
FAQ
What is the main difference between CJC-1295 and sermorelin?
Sermorelin is a 29-amino-acid GHRH fragment with a plasma half-life of roughly 10 to 20 minutes. CJC-1295 with DAC is a 30-amino-acid GHRH analogue conjugated to a Drug Affinity Complex that binds albumin, extending half-life to roughly 6 to 8 days. That difference in duration, not potency per pulse, is the defining practical distinction.
Is tesamorelin FDA-approved?
Yes. Tesamorelin (Egrifta) received FDA approval in 2010 specifically for HIV-associated lipodystrophy in adults. It is the only peptide in this comparison with a formal approved indication and the most robust human RCT evidence base among the four.
Why do people combine CJC-1295 and ipamorelin?
CJC-1295 acts on GHRH receptors to amplify the size of each growth hormone pulse. Ipamorelin acts on ghrelin receptors (GHSR-1a) to increase pulse frequency. The two pathways are additive in animal models, but controlled human data specifically validating the combination are limited. The combination is widely used in anti-aging compounding practices without robust RCT support.
Which peptide has the strongest human evidence for fat loss?
Tesamorelin has by far the strongest evidence. Phase 3 trials in HIV-positive adults with lipodystrophy showed statistically significant visceral adipose tissue reductions averaging roughly 15 to 18 percent versus placebo over 26 weeks. No comparable human RCT data exist for CJC-1295, ipamorelin, or sermorelin in a fat-loss context.
What is the half-life of ipamorelin?
Ipamorelin has a short plasma half-life, reported in pharmacokinetic studies at approximately 2 hours following subcutaneous injection in animal models. Human pharmacokinetic data are limited in the published literature because ipamorelin has not completed clinical drug development.
Does sermorelin actually increase IGF-1 in humans?
Yes, sermorelin has demonstrated measurable IGF-1 increases in controlled studies of GH-deficient children and older adults at doses in the microgram-per-kilogram range. The magnitude of response is smaller than with exogenous GH and declines with age as pituitary reserve diminishes.
Can you take CJC-1295 without DAC or with DAC, and does it matter?
CJC-1295 without DAC is biochemically identical to modified GRF(1-29) with four amino acid substitutions that resist DPP-IV cleavage, giving a half-life of roughly 30 minutes. CJC-1295 with DAC adds albumin-binding chemistry extending half-life to approximately 6 to 8 days, blunting pulsatility. Most practitioners who want preserved GH pulsatility use the without-DAC version dosed immediately before sleep.
What are the main safety risks of these peptides?
Common class effects include water retention, joint aches, carpal tunnel symptoms, and elevated fasting glucose from downstream IGF-1 increases. Tesamorelin's approved labeling lists glucose intolerance as a documented risk. Concerns about IGF-1 elevation and long-term cancer risk remain mechanistically plausible but are not established in short-duration human trials of secretagogues.
Are these peptides banned in sport?
Yes. WADA prohibits all growth hormone releasing peptides and releasing factors on its Prohibited List under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This applies to CJC-1295, ipamorelin, tesamorelin, and sermorelin regardless of the route of administration.
How do you know if a compounded peptide has degraded?
Visual signs of degradation include cloudiness, visible particulate matter, or yellow discoloration in a solution that should be clear and colorless. Functional degradation is harder to detect without HPLC purity testing. Lyophilized powder that has been reconstituted should be refrigerated and used within 28 to 30 days per standard compounding guidance. Loss of expected GH or IGF-1 response over time is a clinical indicator.
Is ipamorelin better than GHRP-2 or GHRP-6?
Ipamorelin is more selective than GHRP-2 or GHRP-6 for the GH axis: it produces less cortisol and prolactin release and essentially no appetite stimulation at standard doses in animal studies, compared to significant cortisol and prolactin spikes with GHRP-6. That selectivity is ipamorelin's primary pharmacological advantage, though head-to-head human data are very limited.
What should I look for on a peptide certificate of analysis?
A credible COA should report HPLC purity (look for greater than 98 percent), mass spectrometry confirmation of the correct molecular weight, sterility testing results (USP 71 or equivalent), endotoxin levels (USP 85, below 5 EU per kg per dose for injectables), and moisture content for lyophilized product. Absence of any of these sections is a red flag.
Sources
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. New England Journal of Medicine. 2007;357(23):2349-2361.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2010;363(23):2249-2259.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
- Walker RF, et al. CJC-1295, a long-acting growth hormone releasing factor (GRF) analogue. Growth Hormone and IGF Research. 2006;16(3):173-179. (Walker et al. 2006 describing n=65 healthy adults, DAC-extended half-life data.)
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
- Arvat E, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1169-1174.
- FDA. Egrifta (tesamorelin) prescribing information. 2010. Available at: fda.gov.
- WADA. Prohibited List 2024. World Anti-Doping Agency. Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.
- Thor
Related peptide guides